Table 2

Overview of included trials

Study, year (reference)

Comparisons (initial drug-dosages)

Sample size (total, included in analysis)

Age group (years)

Follow-up (mean, years)


VA II 1970 [43]

Hydrochlorothiazide (50 mg/day) + reserpine (0.1 mg/day) + hydralazine hydrochloride (25 mg/day) vs. placebo

380

30 to 73

3.3


Oslo hypertension study 1980 [27]

Hydrochlorothiazide (50 mg/day) vs. no treatment

785

40 to 49

5.5


EWPHE 1985 [44]

Hydrochlorothiazide (25 mg/day) + triamteren (50 mg/day) vs. placebo

840

> 60

4.7


Coope 1986 [45]

Atenolol (100 mg/day) or bendrofluazide (5 mg/day) vs. no treatment

884

60 to 79

4.4


HAPPHY 1987 [28]

Bendroflumethiazide (5 mg/day) or hydrochlorothiazide (50 mg/day) vs. atenolol (100 mg/day) or metoprolol 200 mg/day)

6,569

40 to 64

3.8


STOP 1 1991 [46]

Atenolol (50 mg/day) or HCTZ (25 mg/day) (add-on drugs: amiloride (2.5 mg/day) or metoprolol (100 mg/day) or pindolol (5 mg/day)) vs. placebo

1,627

70 to 84

2


SHEP 1991 [26]

Chlortalidone (12.5 mg/day) vs. placebo

4,736

> 60

4.5


MRC 2 1992 [29]

Hydrochlorothiazide+amiloride (25 + 2.5 mg/day) vs. atenolol (50 mg/day) vs. placebo

4,396

65 to 74

5.8


SYST-EUR 1997 [47]

Nitrendipine (10 mg/day) vs. placebo

4,695

> 60

4


Sun 1997 [25]

Nitrendipine (10 mg/day) (starting dose: 10 mg × 3, reduced to 10 mg × 1) vs. usual care

2,080

> 15

4.7


CAPPP 1999 [30]

Captopril (50 mg/day) vs. atenolol (50 to 100 mg/day) or metoprolol (50 to 100 mg/day) or hydrochlorothiazide (25 mg/day) or bendroflumethiazide (2.5 mg/day)

10,985

25 to 66

6.1


NICS-EH 1999 [31]

Nicardipine (20 mg × 2/day) vs. Trichlormethiazide (2 mg/day)

414

≥ 60

4.6 (nicardipine group) and 3.9 (trichlormethia-zide group)


STOP-2 1999 [32]

Atenolol (50 mg/day) or metoprolol (100 mg/day) or pindolol (5 mg/day) or hydrochlorothiazide (25 mg/day)+amilorid (2.5 mg/day) vs. enalapril (10 mg/day) or lisinopril (10 mg/day) vs. felodipine (2.5 mg/day) or isradipine (2.5 mg/day)

6,614

70 to 84

4 to 6


ALLHAT 2000, 2002 [10,33]

Doxazosine (2 mg/day) vs. chlorthalidone (12.5 mg/day) vs. amlodipine (2.5 mg/day) vs. lisinopril (10 mg/day)

42,424

> 55

4.9 for chlorthalidone vs. amlodipine vs. lisinopril.

3.3 (median) for chlorthalidone vs. doxazosine


NORDIL 2000 [34]

Diltiazem (180 to 360 mg/day) vs. thiazide (not specified) or beta-blocker (not specified)

10,881

50 to 74

4.5


INSIGHT 2000 [35]

Nifedipine (30 mg/day) vs. hydrochlorothiazide (25 mg/day)+amilorid (2.5 mg/day)

6,321

55 to 80

~3.5


LIFE 2002 [36]

Losartan (50 mg/day) vs. atenolol (50 mg/day)

9,193

55 to 80

4.8


ANBP 2 2003 [37]

ACE-inhibitor (unspecified type and dosage) vs. thiazide-diuretic (unspecified type and dosage)

6,083

65 to 84

4.1


CONVINCE 2003 [38]

Verapamil (180 mg/day) vs. atenolol (50 mg/day) or hydrochlorothiazide (12.5 mg/day)

16,602

> 55

3


HYVET-PILOT 2003 [39]

Lisinopril (2.5 mg/day) vs. bendroflumethiazide (2.5 mg/day) vs. no treatment

857

> 80

1.1


SHELL 2003 [40]

Chlorthalidone (12.5 mg/day) vs. lacidipine (4 mg/day)

1,882

> 60

2.7 (median)


VALUE 2004 [49]

Valsartan (80 mg/day) vs. amlodipine (5 mg/day)

15,245

> 50

4.2


E-COST 2005 [41]

Candesartan (4 or 8 mg/day) vs. "conventional based regimen"

1,630

35 to 79

3.1


CASE-J 2008 [42]

Candesartan (8 mg/day) vs. amlodipine (5 mg/day)

4,703

63.8 (mean)

3.2


HYVET 2008 [48]

Indapamid (1.5 mg/day) vs. placebo

3,845

≥ 80

2.1


Fretheim et al. BMC Medicine 2012 10:33   doi:10.1186/1741-7015-10-33

Open Data